DE MERCANTI, STEFANIA FEDERICA

DE MERCANTI, STEFANIA FEDERICA  

SCIENZE CLINICHE E BIOLOGICHE  

Mostra records
Risultati 1 - 20 di 45 (tempo di esecuzione: 0.035 secondi).
Titolo Data di pubblicazione Autore(i) File
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 2009 Giulia Contessa; Stefania De Mercanti; Lorenza Delfico; Rossella Sciolla; mario Coletti Moja; Bruno Ferrero; Cinzia Ferrero; Paolo Ripellino; Emanuela Viglietta; Delon La Puma; Luca Durelli
A real-world study of Alemtuzumab in a cohort of Italian patients 2019 Sacca, F; Russo, CV; Frau, J; Annovazzi, P; Signoriello, E; Bonavita, S; Grasso, R; Clerico, M; Cordioli, C; Laroni, A; Capobianco, M; Clerici, VT; Sartori, A; Cavalla, P; Maniscalco, GT; La Gioia, S; Caleri, F; Giugno, A; Iodice, R; Carotenuto, A; Cocco, E; Fenu, G; Zaffaroni, M; Baronicini, D; Lus, G; Gallo, A; De Mercanti, SF; Lapucci, C; Di Francescantonio, V; Sormani, MP; Signori, A
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 2016 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 2016 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 2012 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study 2018 Rolla, S; Bardina, V; Ferrocino, I; De Mercanti, S; Via, AG; Lamberti, A; Lanzillo, R; Bonavita, S; Esposito, S; Giordano, M; Cocolin, LS; Clerico, M
Are arterial hypertension and diabetes modifiers of ALS phenotype and outcome? A population-based study 2015 Calvo, A; Moglia, C; Canosa, A; Bertuzzo, D; Galmozzi, F; Cugnasco, P; Clerico, M; De Mercanti, S; Bersano, E; Cammarosano, S; Ilardi, A; Manera, U; Sideri, R; Marinou, K; Bottacchi, E; Pisano, F; Cantello, R; Mazzini, L; Mora, G; Chiò, A
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 2015 De Mercanti, S; Artusi, Ca; Clerico, M; Iudicello, M; Vacca, A; Virgilio, E; Durelli, L
Atypical presentation of superficial sclerosis successfully treated with iron chelation 2013 De Mercanti S; Iudicello M; Clerico M; Piazza F; Gibbin M; Longo F; Durelli L
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 2015 Barbero, P; Artusi, Ca; De Mercanti, S; Tinivella, M; Busso, M; Clerico, M; Durelli, L
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 2010 Luca Durelli; Marinella Clerico; Simona Rolla; Giulia Contessa; Stefania De Mercanti; Antoni Uccelli; Mauro Zaffaroni; Paola Cavalla; Luciano Rinaldi; Cristoforo Comi; Roberto Cavallo; Luisa Sosso; Francesco Novelli
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 2017 Iannello A., Ferrero G., Maglione A., Cordero F., Rolla S., Bardina V., De Mercanti S., Durelli L., Clerico M., Cutrupi S.
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 2016 De Mercanti, S; Durelli, L; Iudicello, M; Artusi, Ca; Barbero, P; Guerrasio, A; Clerico, M
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 2016 De Mercanti, S.F.; Durelli, L.; Iudicello, M.; Artusi, C.A.; Barbero, P.; Guerrasio, A.; Clerico, M.
Epigenetic mechanisms regulate T helper 17 and T regulatory cells during pregnancy in multiple sclerosis. 2018 Rolla Simona, Bardina Valentina, Iannello Andrea, Maglione Alessandro, De Mercanti Stefania, Puorro Giorgia, Lanzillo Roberta, Cordioli Cinzia, Turrini Mariavittoria, De Bortoli Michele, Cutrupi Santina, Clerico Marinella.
Epigenetic Therapy for Friedreich’s Ataxia: A Phase I Clinical Trial 2014 Jacoby, D.; Rusche, J.; Iudicello, M.; De Mercanti, S.; Clerico, M; Gibbin, M.; Longo, F.; Miao, W.; Rai, M.; Piga, A.; Pandolfo, M.; Durelli, L.
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 2015 Clerico, M; Cutrupi, S; Rolla, S; De Mercanti, S; Iannello, A; Virgilio, E; De Bortoli, M; Durelli, L
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 2016 Marinella, Clerico; Santina, Cutrupi; De Mercanti Stefania, ; Simona, Rolla; Andrea, Iannello; Giulio, Ferrero; Bortoli Michele, De; Luca, Durelli
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 2016 Clerico, M.; Cutrupi, S.; De Mercanti, S.; Rolla, S.; Iannello, A.; Ferrero, G.; De Bortoli, M.; Durelli, L. .
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 2015 Clerico, M; Cutrupi, S; De Mercanti, S; Virgilio, E; Iannello, A; De Bortoli, M; Durelli, L